Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients

Transplantation Proceedings

Volumn 37, Issue 9, 2005, Pages 3766-3767

  Diaz Pedroche C ^a   Lumbreras, C ^a   Del Valle, P ^a   San Juan, R ^a   Hernando, S ^a   Folgueira, D ^a   Andres A ^a   Delgado, J ^a   Meneu, J C ^a   Morales, J M ^a   Moreno, E ^a   Aguado, J M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VALGANCICLOVIR;

ANTIGEN DETECTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFECTION PREVENTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RELAPSE; SAMPLE SIZE; TREATMENT OUTCOME;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 29544450034     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.10.075     Document Type: Conference Paper

References (5)

1. R. Patel, C.V. Payá Infections in solid organ transplant recipients Clin Microbiol Rev 10 1997 86
2. J.M. Cocohoba, I.R. McNicholl Valgancyclovir an advance in cytomegalovirus therapeutics Ann Pharmacother 36 2002 1075
3. R. Casillo, M. Grimaldi, E. Ragone Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients Transplant Proc 36 2004 651
4. N. Singh Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients Clin Infect Dis 32 2001 742
5. F.M. Mattes, E.G. Hainsworth, A.F. Hassan-Walker Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valgancyclovir J Infect Dis 191 2005 89